<DOC>
	<DOC>NCT00333086</DOC>
	<brief_summary>Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.</brief_summary>
	<brief_title>A Study of Letrozole in the Treatment of Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criteria Postmenopausal women with recurrent or metastatic adeno or adenosquamous carcinoma of the endometrium No adjuvant therapy Up to one prior hormonal (progestin) therapy for advanced/metastatic disease allowed No chemotherapy for recurrence (adjuvant permitted) Unidimensionally measurable disease Good Health status 02 (Eastern Cooperatitve Oncology Group) No prior tamoxifen or aromatase inhibitor therapy No other concurrent anticancer treatment No metastases in the central nervous system Exclusion criteria: Additional protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Letrozole</keyword>
</DOC>